Denver, Colorado – Markets are experiencing a cross-sector mix of breakthrough science, regulatory acceleration, global expansion, and next-generation infrastructure demand. From advanced materials to immunotherapy and AI-enabling semiconductors, several names pushing to new 52-week highs today appear to have fundamental narratives that could sustain upside.
Advanced Materials Break Out
Shares of Kraig Biocraft Laboratories (OTCQB:KBLB) are pressing into new 52-week high territory after its recombinant spider silk technology was featured on the cover of the March 2026 issue of National Geographic.
The feature, The Quest for Spider Silk, spotlighted the company’s genetically engineered silkworm platform capable of producing spider silk fibers within the insect’s natural biological process. Demonstrations included towing a car and suspending a person with a lightweight silk loop, visually reinforcing the material’s exceptional strength-to-weight profile.
The media attention coincides with a critical production ramp. Kraig Labs is deploying approximately one million proprietary spider silk silkworm eggs across three facilities in Vietnam, targeting up to 10 metric tons of cocoons per month beginning in March.
If sustained, Kraig could become only the second company to achieve commercial-scale output from a transgenic animal platform, a milestone historically associated with ATryn, later incorporated into Sanofi following its acquisition of Genzyme.
With prior disclosures referencing engagement with global brands in luxury fashion, performance sportswear, and athletic equipment, investors are watching closely for confirmation of initial deliveries. A technical breakout aligned with a production inflection point often creates the type of setup momentum traders favor.
24/7 Market News encourages readers and industry observers to obtain a copy of this month’s National Geographic to review the full feature and explore the scientific context in depth. Interested persons can order a copy of the magazine from National Geographic at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.
You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering
** Photography by Mark Thiessen, NGM Staff, Image Copyright: National Geographic Magazine
Oncology Platform Acceleration
ImmunityBio (NASDAQ:IBRX) has also been trading at new 52-week highs following explosive commercial and regulatory expansion for ANKTIVA.
The company reported approximately $113 million in full-year 2025 net product revenue, a ~700% year-over-year increase, alongside a 750% surge in unit sales volume. Q4 revenue alone reached $38.3 million, up 431% year-over-year.
Global regulatory authorizations now span 33 countries across the United States, United Kingdom, European Union, and Saudi Arabia. Notably, Saudi regulators granted the first approval of ANKTIVA in combination with checkpoint inhibitors for metastatic non-small cell lung cancer, marking the therapy’s expansion beyond bladder cancer.
With multiple Phase 3 and randomized trials underway and patent protection extending beyond 2035, investors appear to be re-rating ImmunityBio from a development-stage biotech to a global commercial oncology platform. Breakouts supported by revenue acceleration and regulatory momentum often have room to run if execution continues.
Strategic Biotech Collaboration
Vir Biotechnology (NASDAQ:VIR) is trading near fresh highs after announcing a major global oncology collaboration with Astellas Pharma for its PSMA-targeted PRO-XTEN T-cell engager, VIR-5500.
The agreement includes $335 million in upfront and near-term payments, including a $75 million equity investment at a 50% premium, and up to $1.37 billion in potential milestones.
Updated Phase 1 data showed no dose-limiting toxicities, 82% PSA50 declines in higher-dose cohorts, and a 45% objective response rate among RECIST-evaluable patients.
With $781.6 million in cash and projected runway into 2028, Vir has both validation and capital. Biotech names breaking to new highs on strategic validation and improved balance sheets often attract sustained institutional interest.
AI Infrastructure Supply Chain
While not yet a classic breakout leader, AXT (NASDAQ:AXTI) is gaining attention as a foundational supplier to the AI infrastructure build-out, particularly in indium phosphide substrates.
Management cited 2026 export permit approvals and expectations for sequential Q1 growth driven by AI-related demand. The company is also on track to double indium phosphide capacity this year.
As hyperscale compute expansion continues, materials suppliers leveraged to optical interconnects and advanced photonics may see accelerating order visibility. If revenue growth returns alongside margin stabilization, AXTI could transition from recovery narrative to momentum candidate.
Dividend Stability in a Classic Tape
Corning (NYSE:GLW) declared a quarterly dividend of $0.28 per share payable March 30, to February 27 shareholders of record, reinforcing capital return stability amid broader tech volatility. While not a high-beta breakout story, income-oriented capital often rotates into established materials leaders during uncertain rate environments.
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.